ArticlemSphere2019
First Report of
Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Pan-genome analysis of the Enterobacter hormaechei complex highlights its genomic flexibility and pertinence as a multidrug resistant pathogen.BMC genomics · 2025Article
- Quinolone Resistance Genes qnr, aac(6')-Ib-cr, oqxAB, and qepA in Environmental Escherichia coli: Insights into Their Genetic Contexts from Comparative Genomics.Microbial ecology · 2025Article
- Distinct molecular epidemiology of resistances to extended-spectrum cephalosporins and carbapenems in Enterobacter hormaechei in cats and dogs versus horses in France.The Journal of antimicrobial chemotherapy · 2025Article
- The multifaceted roles of phosphoethanolamine-modified lipopolysaccharides: from stress response and virulence to cationic antimicrobial resistance.Microbiology and molecular biology reviews : MMBR · 2024Review
- Polymyxin resistance in Enterobacter cloacae complex in Brazil: phenotypic and molecular characterization.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Article
- More thanFrontiers in cellular and infection microbiology · 2023Article
- Virulence factors in carbapenem-resistant hypervirulentFrontiers in microbiology · 2023Review
- First report of coexistence ofFrontiers in microbiology · 2023Article
- Frequent convergence ofEmerging microbes & infections · 2022Article
- AreFoods (Basel, Switzerland) · 2022Article
- Occurrence ofAntibiotics (Basel, Switzerland) · 2022Article
- First Case Report of Detection of Multidrug-ResistantMicroorganisms · 2022Article
- A prospective matched case-control study on the genomic epidemiology of colistin-resistant Enterobacterales from Dutch patients.Communications medicine · 2022Article
- Molecular characterization of NDM-1-producing carbapenem-resistantFrontiers in cellular and infection microbiology · 2022Article
- Co-occurrence of dual carbapenemases KPC-2 and OXA-48 with the mobile colistin resistance geneFrontiers in cellular and infection microbiology · 2022Article
- Global epidemiology, genetic environment, risk factors and therapeutic prospects ofFrontiers in cellular and infection microbiology · 2022Review
- Molecular antibiotic resistance mechanisms and co-transmission of theFrontiers in microbiology · 2022Article
- AFrontiers in cellular and infection microbiology · 2022Article
- Colistin-resistant Enterobacter kobei carrying mcr-9.1 and blaTransboundary and emerging diseases · 2021Article
- Complete Genome Sequence of anMicrobiology resource announcements · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
An
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.